OUR FUNDING STRATEGY
Our goal is to accelerate the best ideas in Parkinsonís disease research toward clinical testing and practical relevance for patients. By placing a strong emphasis on translational and clinical research, we ensure that new ideas are constantly flowing into the drug development pipeline.
Sitting at the nexus of Parkinsonís research worldwide, we are constantly building and refining our understanding of the therapeutic needs of Parkinsonís patients. Our research agenda is crafted around these needs, reflecting two key areas:
- Research exploring specific therapeutic approaches that could contribute to the development of improved Parkinson's disease treatments
- Research to develop tools and resources that will help accelerate the development of Parkinson's disease treatments
Through our annual Pipeline Strategy, we constantly seek new ideas, relevant biological targets and promising therapeutics that can benefit people with Parkinsonís disease. In addition, our team of experts looks for challenge areas where the Foundation's proactive effort can accelerate the development of new and improved treatments. Priority areas allow the Foundation to quickly deploy resources and expertise where it is needed most.
A major focus of therapeutic development given its genetic link and presence in Lewy bodies, the cardinal neuropathological feature of Parkinsonís disease.
Biomarkers are critical for identifying and tracking the progression of Parkinsonís disease, as well as detecting how drugs act in the body.
Not well managed by existing treatments, cognitive impairment is a major Ēnon-motorĒ feature of Parkinsonís disease that can drastically reduce quality of life.
A major side effect of gold-standard levodopa therapy, dyskinesias can be highly disabling and reduce overall quality of life for Parkinsonís patients.
Imaging is a powerful tool that can be used to visualize the structure and function of the brain in living subjects.†An imaging biomarker would be extremely useful both for drug development studies and as an outcome measure in clinical trials.†
A compelling drug target given its strong genetic link to Parkinsonís disease and highly ďdruggableĒ cellular function.
Essential for developing and maintaining healthy neurons, neurotrophic factors could help protect and restore function in damaged dopamine neurons in the brains of Parkinsonís patients.
Our Pipeline Strategy, including annual funding programs, is the Foundation's flagship mechanism for funding new and promising research projects.
The Foundation offers a variety of critical tools and resources to help investigators spend more time focusing on what matters: curing Parkinsonís disease.
Accelerate Your Research
Want Research Updates?
Receive e-news from MJFF about funding opportunities, scientific conferences, and more.
Access Research Tools
Select from pre-clinical models, reagents, research data and more.
We work with Industry
More than $102†million in funding to over†230†unique industry-led projects
Connect With Other Researchers